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Background:  Recent  advances  in drug-eluting  stent  (DES)  technology  have  succeeded  in reducing  resteno-
sis.  However,  the  use of  DES  is reportedly  equivalent  to bare  metal  stents  in  terms  of  long-term  survival.
In  addition,  stent  materials  represent  foreign  bodies,  which  if  possible  should  not ideally  be  left  within  the
patient.  On  these  bases,  an  investigation  was performed  into  the  feasibility  of  a new  approach,  ‘stentless’
percutaneous  coronary  intervention  (PCI),  using  a  Lacrosse® non-slip  element  (NSE)  balloon  (Goodman
Co.,  Ltd.,  Nagoya,  Japan).
Methods and results:  In our  ‘stentless’  approach,  the  NSE  balloon  is used  for target  lesion  dilation  in
patients  with  low  risk  factors  and  simple  target  lesions.  No  stenting  was  performed  once  an  optimal
dilatation  result  was  achieved,  as evaluated  by  intravascular  ultrasound  (IVUS).  In a  total  of 340 lesions
in  304  patients,  in whom  the  follow-up  study  was  completed,  the  ‘stentless’  PCI  by NSE balloon  alone  was
achieved  in 52  lesions  (15%).  Target  lesion  revascularization  (TLR)  was  performed  for 5  (9.6%)  of  the  52
‘stentless’  lesions.  In  the  comparison  between  the  52 ‘stentless’  lesions  and  the 31  DES lesions  selected
under  the  statistical  matching  of the  patient  proﬁles  and  baseline  lesion  characteristics,  the  TLR rate  (9.6%
vs  6.5%,  p  = 0.616)  and  late  lumen  loss  (0.52  ± 0.26  mm  vs  0.48  ±  0.21  mm,  p = 0.347)  were  similar.  In  the
52  ‘stentless’  lesions,  IVUS  parameters  such  as vessel  area,  minimal  lumen  area,  and plaque  area  at  both
before  and  immediately  after  PCI  were  similar  between  the 5  TLR  lesions  and  the  47  non  TLR  lesions.
Conclusions: It is  believed  that  the  ‘stentless’  approach  is  applicable  even  in the  DES era.
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Recent advances in drug-eluting stent (DES) technology have
ucceeded in reducing restenosis, which has long been a major
eakness of percutaneous coronary intervention (PCI). However,
he use of DES is reportedly equivalent to bare metal stents (BMS) in
erms of long-term survival [1,2]. A new concern beyond restenosis
as arisen due to the potential for delayed vessel wall healing by the
mpairment of reendothelialization, i.e. endothelial regeneration
n the surface of the stent strut after DES stenting [3–6]. Also, recent
vidence suggests that DES impairs the endothelial function in the
istal segment of the stented site [7–9] and/or in the microvascula-
ure of the DES-implanted coronary artery [10]. Anatomical as well
s functional endothelial impairment may  in part account for the
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fact that the DES does not contribute to improvements in long-term
prognosis.
In addition, not only DES but also BMS have the limitations
of metallic implants such as artifacts in in-stent lumen visualiza-
tion by standard magnetic resonance and computed tomography
angiography, problems of post-PCI coronary artery bypass graft-
ing, metal allergy, and other unknown long-term adverse effects.
On these bases, it is hypothesized that a ‘stentless’ approach (bal-
loon angioplasty alone) should be given careful consideration as a
choice for PCI strategy, even in the DES era.
Previously, patients undergoing balloon angioplasty alone
incurred restenosis rates of approximately 40–50%. Therefore, even
in the era of balloon angioplasty alone, 50–60% of patients were free
from restenosis. Post-angioplasty intravascular ultrasound (IVUS)
ﬁndings such as large plaque burden, cross-sectional luminal nar-
rowing, and major dissection were noted to predict development
of restenosis after balloon angioplasty [11,12].The Lacrosse® non-slip element (NSE) balloon (Goodman Co.,
Ltd., Nagoya, Japan) is an angioplasty catheter with 3 longitudinal
elements attached directly proximal and distal to the balloon that
produces 3 endovascular surgical incisions during balloon dilation.
vier Ltd. All rights reserved.
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esion dilation under surgical incisions may  be expected to reduce
oop stress during the dilation, and thus, resulting in plaque reduc-
ion and large luminal gain.
We have actively undertaken the ‘stentless’ approach using an
SE balloon in appropriate cases as an initial PCI strategy. To verify
ur hypothesis, this time we investigated the feasibility of this new
pproach.
ethods
trategy for a ‘stentless’ PCI approach
Since September, 2009, initial elective PCI for patients with
hronic coronary artery disease that satisﬁed the following enrol-
ent criteria was performed at our facility: patient criteria
ncluding no poor-controlled diabetes deﬁned as a hemoglobin A1c
evel over 6.5% by the National Glycohemoglobin Standardization
rogram (NGSP) criteria with or without diabetic treatments and
ithout undergoing hemodialysis treatment; target lesion crite-
ia including no evidence of calciﬁcation, chronic total occlusion
r bifurcated lesions; lesion length < 20 mm and reference diame-
er ≥ 3.0 mm.  Initial dilatation of the lesions was performed using
n optimal size NSE balloon. Balloon size was determined as 90%
f vessel diameter evaluated by IVUS with balloon inﬂation pres-
ure from nominal to rated burst (6–14 atm). Inﬂation time was
0–60 s, and frequency of inﬂation was not limited. Once an opti-
al dilatation result was achieved, as evaluated by intravascular
ltrasound (IVUS) in addition to coronary angiography (CAG) ﬁnd-
ngs, no stenting was undertaken. The optimal dilatation result was
eﬁned as: minimum lumen area ≥ 5.0 mm2; no major dissection
deﬁned as length ≥ 20 mm or a decrease in lumen area > 30%) by
oth CAG and IVUS. If an optimal lesion dilation result was  not
chieved, a BMS  or DES was implanted. For those lesions that did
ot satisfy the lesion criteria for a ‘stentless’ approach, planned
tenting using a BMS  or DES was the primary treatment strategy. In
atients who had poorly controlled diabetes, who were undergo-
ng hemodialysis and/or who had only complex lesions including
mall vessels, long lesions, chronic total occlusive lesions, bifur-
ated lesions, and/or severe calciﬁed lesions as the target lesions,
lanned stenting with the BMS  or DES (Fig. 1) was determined
s the primary treatment strategy. The choice of BMS  or DES was
Patient criteria: no poorly -controlled diabetes, no hemodialysis
Target lesion criteria: 
reference diameter 3.0 mm, lesion length <20 mm, no chronic total 
occlusion, no calcified lesion , no bifurcated lesion (Total of 340 lesions)
YES NO
Lacrosse® NSE 
balloon
Stent
Optimal result
on CAG and IVUS
YES NO
Follow-up CAG
BMS DES 
Stent
BMS DES 
Operators’ decision
Operators’ decision
(n=59) (n=281)
(n=52)
(n=161) (n=120)
(n=0)
(n=7)
(n=7)
≥
ig. 1. Protocol of ‘stentless’ percutaneous coronary intervention approach shown
n a ﬂow-chart and detailed number of lesions in each ﬂow. NSE, non-slip element;
MS,  bare metal stent; DES, drug-eluting stent; CAG, coronary angiography; IVUS,
ntravascular ultrasound.iology 63 (2014) 19–23
based upon operator discretion, given a concept of DES avoidance
due to the impairment of the wound healing response after DES
placement. PCI for acute coronary syndrome (ACS) and restenosis
lesions were excluded from this strategy. The trial endpoint is the
target lesion revascularization (TLR) rate and late lumen loss at the
6–12 month follow-up period. In principle, TLR was performed in
patients who experienced ≥75% diameter stenosis by quantitative
coronary angiographic (QCA) measurements and/or given ischemic
symptoms.
All of the patients received optimal medical therapies includ-
ing anti-platelet therapy, anti-hypertensive therapy, anti-diabetic
therapy, and lipid-lowering therapy, in addition to PCI. All patients
received aspirin and clopidogrel was further included in cases
with implanted stents. The anti-platelet agents were continued
until follow-up CAG. Statins were administered and continued
in all patients except for those in whom side effects appeared
and/or tolerability was lacking, independent of their lipid lev-
els, with the aim being to reduce low-density lipoprotein (LDL)
cholesterol levels < 70 mg/dl [13], and the patients with LDL choles-
terol level < 70 mg/dl received minimum dose of strong statins or
standard dose of mild statins [14]. For anti-hypertensive treatment,
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs) were administered to all patients except
for those in whom side effects appeared and/or tolerability was
lacking, with the aim to reduce patients’ blood pressure to
<130/80 mmHg. Diabetic patients were aggressively treated with
anti-diabetic agents, while avoiding hypoglycemic events.
Quantitative coronary angiographic analysis
Coronary lesions were assessed by QCA measurements using
a computer-based QCA-CMS system (Medis, Leiden, Netherlands).
The quantitative measurements were performed on end-diastolic
frames from the angiograms by one investigator who was  unaware
of the study design. The reference diameter, lesion length, and mini-
mal  lumen diameter were measured before and after PCI, and also at
time of follow-up CAG. On the basis of these measurements, values
of percent diameter stenosis, acute gain (minimal lumen diame-
ter immediately after PCI minus minimal lumen diameter before
PCI), net gain (minimal lumen diameter at follow-up angiography
minus minimal lumen diameter before PCI), and late lumen loss
(minimal lumen diameter immediately after PCI minus minimal
lumen diameter at follow-up angiography) was obtained for each
lesion.
IVUS procedure
IVUS data were acquired with a 20-MHz, 2.9 Fr, phased-array
IVUS catheter (Eagle Eye Gold, Volcano Corp., Rancho Cordova, CA,
USA) and a dedicated console (IVG3, Volcano Corp.). The catheter
probe was advanced ≥10 mm distal to the most distal side branch.
Angiographic cine runs were performed to deﬁne the position of
the IVUS catheter. Manual pullback was  performed after intracoro-
nary administration of isosorbide dinitrate (2.5 mg)  at before and
immediately after NSE balloon angioplasty, and measured vessel
area, lumen area, and plaque area and evaluated whether major
coronary dissection had occurred.
Statistical analysisValues  are expressed as the mean ± SD. Intergroup comparisons
were performed using unpaired t tests for continuous variables
and chi square tests for categorical variables. A p-value < 0.05 was
considered to be statistically signiﬁcant.
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Discussion
Our ‘stentless’ approach using the NSE balloon alone was con-
ceived based upon the hypothesis that implantation of metallic
Table 2I. Taguchi et al. / Journal 
esults
Up to March, 2011, a total of 575 patients underwent elec-
ive PCI under the strategy for a ‘stentless’ approach. Of these, a
ollow-up study was completed in a total of 304 patients. Of these
04 patients, PCI was performed for 340 target lesions. Of these
40 lesions, an NSE balloon was used for initial target lesion dila-
ion in 59 lesions (17.4%). Of the remaining 281 lesions (82.6%),
tent implantation was initially planned due to the above men-
ioned exclusion criteria for ‘stentless PCI’, i.e. poorly controlled
iabetes (47 lesions; 13.8%), receiving hemodialysis (8 lesions;
.4%), chronic total occlusion (16; 4.7%), bifurcated lesion (32;
.4%), and severe calciﬁed lesion (54 lesions; 15.9%). Of these 281
esions, BMS  was implanted for 161 lesions (47.3%) and DES was
mplanted for 120 lesions (35.3%). In patients undergoing initial
esion dilation using an NSE balloon, optimal results by both CAG
nd IVUS were obtained in 52 lesions (15.3%), and thus, ‘stentless’
CI was achieved. Of the remaining 7 lesions (2.1%), provisional
tenting was performed due to unsatisfactory balloon dilatation
esults, and BMS  and DES were placed for 7 (2.1%) and 0 lesions
0%), respectively (Fig. 1). Overall, ‘stentless’ PCI by an NSE balloon
lone was accomplished in 52 lesions (15.3%), and BMS  and DES
ere implanted for 168 (49.4%) and 120 lesions (35.3%), respec-
ively. In the DES placed lesions, sirolimus eluting stent (SES),
otarolimus eluting stent (ZES), and everolimus eluting stent (EES)
ere implanted for 8, 67, and 45 lesions, respectively. In overall
40 lesions, TLR was performed for 5 (9.6%) of the 52 ‘stentless’
esions, 21 (12.5%) of the 168 BMS  lesions, and 7 (5.8%) of the
20 DES lesions. The overall TLR rate for 340 lesions was  9.7%.
ngiographic late lumen loss was 0.52 ± 0.51 mm in the ‘stentless’
esions, 1.01 ± 0.98 mm in the BMS  lesions, and 0.46 ± 0.58 mm  in
he DES lesions.
From  the 120 DES lesions, we selected 31 lesions (SES, 2; ZES,
6; EES, 13) under the statistical matching of the patient proﬁles
nd baseline lesion characteristics, which we retrospectively com-
ared with the 52 ‘stentless’ lesions. Table 1 shows the comparisons
f patient proﬁles between the 52 ‘stentless’ lesions and the 31
elected DES lesions. In terms of age, gender, presence of hyperten-
ion, diabetes, dyslipidemia, and smoking, the levels of hemoglobin
1c, LDL-cholesterol, high-density lipoprotein (HDL)-cholesterol,
riglyceride, and estimated glomerular ﬁltration rate and prescrip-
ions of statins or ACEIs/ARBs at the follow-up time, there were no
igniﬁcant differences between the two lesion groups. The lesion
haracteristics, QCA analysis results, and TLR in both groups of
he ‘stentless’ lesions and the selected DES lesions are shown in
able 1
atient proﬁles in ‘stentless’ lesions and selected DES.
‘Stentless’
(52 lesions)
Selected  DES
(31  lesions)
p-Value
Age; yr 61 ± 13 64 ± 9 0.23
Male gender; n (%) 42 (81) 20 (65) 0.15
Hypertension; n (%) 24 (46) 21 (68) 0.13
Diabetes; n (%) 13 (39) 15 (48) 0.48
Hemoglobin A1c; % 5.6 ± 0.6 5.8 ± 0.8 0.31
Dyslipidemia; n (%) 36  (69) 19  (61) 0.79
LDL-cholesterol; mg/dl 72 ± 25 72 ± 29 0.82
HDL-cholesterol; mg/dl 46 ± 12 47 ± 13 0.72
Triglyceride; mg/dl 62 ± 48 58 ± 51 0.33
Egfr; ml/min. 74 ± 26 67 ± 21 0.19
Smoking; n (%) 22 (42) 17 (55) 0.26
Medications
Statins; n (%) 52 (100) 29 (94) 0.65
ACEIs/ARBs; n (%) 51 (98) 28 (90) 0.48
ES, drug-eluting stent; LDL, low-density lipoprotein; HDL, high-density lipopro-
ein; eGFR, estimated glomerular ﬁltration rate; ACEIs, angiotensin-converting
nzyme inhibitors; ARBs, angiotensin receptor blockers. Parameters for glucose and
ipid metabolism and medications are those at the follow-up time.iology 63 (2014) 19–23 21
Table 2. Lesion locations, lesion characteristics such as reference
diameter, minimal lumen diameter, and % diameter stenosis at
baseline were similar between both lesion groups. At immediately
after PCI, minimal lumen diameter and acute gain in the ‘stentless’
lesions were less than those in the DES lesions (2.51 ± 0.70 mm
vs 3.02 ± 0.47 mm,  p < 0.001; 1.93 ± 0.73 mm vs 2.26 ± 0.48 mm,
p = 0.027). Percent diameter stenosis in the ‘stentless’ lesions was
greater than that in the selected DES lesions (16.8 ± 10.9% vs
8.8 ± 5.3%, p < 0.001). At the follow-up time, minimal lumen diame-
ter and net gain in the ‘stentless’ lesions were less than those in the
selected DES lesions (1.98 ± 0.75 mm vs 2.45 ± 0.80 mm,  p < 0.01;
1.41 ± 0.79 mm vs 1.78 ± 0.90 mm,  p = 0.043). Percent diameter
stenosis in the ‘stentless’ lesions was  greater than that in the DES
lesions (28.8 ± 18.5% vs 17.2 ± 24.3%, p < 0.023). In terms of late
lumen loss and TLR rate, there were no signiﬁcant differences
between the ‘stentless’ lesions and the DES lesions (0.52 ± 0.26 mm
vs 0.48 ± 0.21 mm,  p = 0.347; 9.6% vs 6.5%, p = 0.616).
Next,  in the limited 52 ‘stentless’ lesions, we compared patient
proﬁles, lesion characteristics, and IVUS analysis data between 5
TLR lesions and 47 non-TLR lesions (Table 3). In terms of age, gen-
der, presence of hypertension, diabetes, dyslipidemia, and smoking,
the levels of hemoglobin A1c, LDL-cholesterol, triglyceride, and
estimated glomerular ﬁltration rate at the follow-up time, there
were no signiﬁcant differences between the two lesion groups.
However, the HDL-cholesterol level tended to be higher in the
non-TLR lesions, compared to the TLR lesions (46.3 ± 12.3 mg/dl
vs 38.4 ± 10.5 mg/dl, p = 0.057). Each of the IVUS parameters such
as vessel area, minimum lumen area, and plaque area in the TLR
lesions was  similar to those in the non-TLR lesions both at baseline
before PCI and immediately after PCI. In particular, minimum lumen
area immediately after PCI was  6.2 ± 0.8 mm2 vs 6.5 ± 2.1 mm2
(p = 0.827) in the TLR lesions and non-TLR lesions, respectively. In
addition, lesion length, balloon size, and balloon inﬂation pressure
were also similar between the two lesion groups.Lesion characteristics, QCA data, and endpoint analysis.
‘Stentless’
(52 lesions)
Selected  DES
(31  lesions)
p-Value
Lesion location
LAD;  n (%) 26 (50.0) 13 (41.9) 0.59
LCx; n (%) 7 (13.5) 10 (32.3) 0.125
RCA; n (%) 19 (36.5) 8 (25.8) 0.371
AHA lesion classiﬁcation (A/B/C) (3/49/0) (1/30/0) 0.807
Before PCI
Lesion  length; mm 12.3 ± 5.3 12.8 ± 4.4 0.593
RD; mm 2.90 ± 0.80 2.80 ± 0.39 0.568
MLD; mm 0.58 ± 0.42 0.76 ± 0.42 0.469
%DS 79.8 ± 13.5 73.2 ± 14.0 0.062
Immediately after PCI
MLD; mm 2.51 ± 0.70 3.02 ± 0.47 <0.001
%DS 16.8 ± 10.9 8.8 ± 5.3 <0.001
Acute gain; mm 1.93 ± 0.73 2.26 ± 0.48 0.027
Follow up data
MLD;  mm 1.98 ± 0.75 2.45 ± 0.80 <0.01
%DS 28.8 ± 18.5 17.2 ± 24.3 0.023
Net gain; mm 1.41 ± 0.79 1.78 ± 0.90 0.43
Late lumen loss; mm 0.52 ± 0.26 0.48 ± 0.21 0.347
TLR; n (%) 5 (9.6) 2 (6.5) 0.616
QCA, quantitative coronary angiography; DES, drug-eluting stent; LAD, left ante-
rior descending artery; LCx, left circumﬂex artery; RCA, right coronary artery; AHA,
American Heart Association; PCI, percutaneous coronary intervention; RD, refer-
ence diameter; MLD, minimal lumen diameter; %DS, percent diameter stenosis; TLR,
target lesion revascularization.
22 I. Taguchi et al. / Journal of Card
Table 3
Comparison between of TLR lesions and non-TLR lesions after the ‘stentless’.
TLR (5 lesions) Non-TLR
(47 lesions)
p-Value
Age; yr 64  ± 5 59 ± n 0.191
Male gender; n (%) 5 (100) 37 (79) 0.217
Hypertension; n (%) 1 (20) 23 (49) 0.152
Diabetes; n (%) 1 (20) 15 (32) 0.322
Hemoglobin A1c (%) 5.4 ± 0.4 5.7 ± 0.8 0.084
Dyslipidemia; n (%) 5 (100) 31(66) 0.283
Lipid parameters at follow up
LDL-cholesterol; mg/dl 79.0 ± 17.0 71.1 ± 16.9 0.323
HDL-cholesterol; mg/dl 38.4 ± 10.5 46.3 ± 12.3 0.057
Triglyceride; mg/dl 89.6 ± 61.4 58.6 ± 30.8 0.163
eGFR; ml/min. 81.8 ± 5.7 73.3 ± 17.5 0.292
Smoking; n (%) 3 (60) 19 (40) 0.461
IVUS before PCI
Vessel  area; mm2 16.5 ± 4.6 15.8 ± 5.2 0.81
Minim lumen area; mm2 2.7 ± 0.6 2.6 ± 0.2 0.76
Plaque area; mm2 13.8 ± 3.9 13.2 ± 5.0 0.815
IVUS immediately after PCI
Vessel area; mm2 17.2 ± 4.2 17.1 ± 5.6 0.974
Minim lumen area; mm2 6.2 ± 0.8 6.5 ± 2.1 0.827
Plaque area; mm2 11.0 ± 3.7 10.6 ± 3.9 0.873
Lesion length; mm 11.5 ± 2.9 12.2 ± 4.9 0.798
Balloon size; mm 3.65 ± 0.34 3.43 ± 0.54 0.384
Balloon inﬂation pressure; atm 12.8 ± 1.8 11.3 ± 3.9 0.404
TLR, target lesion revascularization; LDL, low-density lipoprotein; HDL, high-density
lipoprotein;  TG, triglyceride; eGFR, estimated glomerular ﬁltration rate; IVUS,
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lucose and lipid metabolism and medications are those at the follow-up time.
tents could be avoided in limited cases of simple lesions, i.e.
hort lesions within a large vasculature (excluding chronic total
cclusion lesions, severe calciﬁed lesions, or bifurcated lesions) in
on-diabetic and non-hemodialysis patients with chronic coronary
rtery disease. Consequently, the ‘stentless’ PCI was  accomplished
n 15.3% of the all lesions treated with PCI in an elective fashion. In
hese lesions, TLR rate was  9.6%, and it was 12.5% in the BMS  lesions
nd 5.8% in the DES lesions. Even in the comparison of the ‘stentless’
esions with the DES lesions selected under the statistical match-
ng of the patient proﬁles and baseline lesion characteristics, the
LR rate and late lumen loss were similar between the two  groups
f the lesions. These results suggest that even NSE balloon angio-
lasty alone would achieve a DES-equivalent TLR rate, if we select
atients and lesions suitable for ‘stentless’ PCI.
The NSE balloon is an angioplasty catheter, in which 3 longi-
udinal synthetic resin elements mounted on the balloon surface
revent a balloon slip phenomenon during balloon inﬂation.
imultaneously, the longitudinal elements produce 3 endovascu-
ar surgical incisions during balloon dilation because of their sharp
eometry. As a result, it is theoretically feasible that elastic recoil
an be reduced, and traumatic vessel wall injury and dissection
an be limited. Thus, the concept of lesion dilation by an NSE bal-
oon is similar to that of a cutting balloon. The cutting balloon,
n which 3 or 4 microtome sharp metal blades are mounted, was
esigned by Barath et al. [15]. The 3 or 4 radially directed micro-
urgical blades create longitudinal vascular incisions before the
alloon inﬂation is completed, and balloon pressure serves primar-
ly to propagate these incisions. Thus, unfavorable vascular injury
s controlled and localized to the area of the incisions and interin-
isional segments are spared. Cutting balloon angioplasty prior to
MS  has been reported to have some impact on restenosis reduc-
ion in the Japanese trial, REstenosis reDUction on Cutting balloon
valuation trial III (REDUCE III) [16]. However, the cutting bal-
oon has a limitation in cross-ability of the lesion due to the metal
lade component. In contrast, the NSE balloon demonstrates sev-
ral advantages over the cutting balloon in terms of its ﬂexibility
nd proﬁle characteristics that exhibit better cross-ability, and thus,iology 63 (2014) 19–23
would see more frequent use. We  previously reported that cut-
ting balloon angioplasty reduced PCI-induced local inﬂammatory
response as demonstrated by less up-regulation of integrin Mac-1
(CD11b/CD18) on the surface of neutrophils, compared with con-
ventional balloon angioplasty [17]. Further observation indicated
that PCI-induced Mac-1 up-regulation was greater in BMS stenting,
compared with conventional balloon angioplasty [18]. Therefore,
we believe that the NSE balloon would produce further reduction
of inﬂammatory response, compared to BMS.
In our approach, the optimal dilatation result was  deﬁned as
the minimum lumen area ≥ 5.0 mm2, which seems to be small
for the prevention of restenosis after balloon angioplasty alone.
In general, the TLR rate post BMS  implantation was 5.8% in the
lesions, in which minimum lumen area ≥ 6.5 mm2, corresponding
to a minimal lumen diameter ≥ 2.9 mm,  was achieved [19]. How-
ever, it is difﬁcult to acquire the same acute gain as BMS, using
NSE balloon alone. Considering less inﬂammatory response by NSE
balloon angioplasty, compared with BMS  stenting, we  believe that
minimum lumen area ≥ 5.0 mm2, corresponding to minimal lumen
diameter ≥ 2.5 mm,  might be a relevant value for the optimal result
of post ‘stentless’ PCI by the NSE balloon alone. In our results, min-
imal lumen area immediately after ‘stentless’ PCI was  statistically
similar in both TLR lesions and non-TLR lesions under the endpoint
of the ‘stentless’ approach such as ≥5.0 mm2.
Another  important ﬁnding in our study is the comparison of
IVUS parameters between TLR and non-TLR lesions in the limited
lesions treated by the ‘stentless’ approach with the NSE balloon
alone. As a result, vessel area, minimal lumen area, and plaque
area at both before and immediately after PCI are quite similar
between the TLR lesions and non-TLR lesions. Namely, TLR after
the ‘stentless’ PCI developed independently of the dilation results
immediately post PCI. The results also support the deﬁnition of our
optimal result criteria for the ‘stentless’ PCI evaluated by IVUS (min-
imum lumen area ≥ 5.0 mm2) and may  be relevant in the clinical
setting. In addition, age, gender, presence of hypertension, dia-
betes, dyslipidemia, and smoking, the levels of hemoglobin A1c,
LDL-cholesterol, triglyceride, and estimated glomerular ﬁltration
rate at the follow-up time were similar between the two lesion
groups. However, the HDL-cholesterol level tended to be higher in
the non-TLR lesions, compared to the TLR lesions, suggesting that
HDL-cholesterol treatment may  be one of the targets for improve-
ment of prognosis of the ‘stentless’ PCI. In addition, further medical
treatments targeting oxidized LDL-C [20], inﬂammation, metabolic
syndrome, and chronic kidney disease [21] would be promising.
Study  limitations
This  was a retrospective single center study with a small sample
size, therefore to recognize the value of ‘stentless’ PCI in the clinical
setting needs a prospective randomized multicenter trial with a
large number of participants. In this study, IVUS was performed
for only evaluation of the optimal result for post ‘stentless’ PCI.
However, IVUS parameters including volume data at every point
would be needed. Although, in our results, minimum lumen area
immediately after the ‘stentless’ PCI was  similar in TLR lesions and
non-TLR lesions, TLR cases in ‘stentless’ PCI group were only 5, so
we cannot deﬁne statistically the rationale for a speciﬁc value of
≥5.0 mm2 as endpoint minimum lumen area. However, we believe
that the fact that endpoint as minimum lumen area ≥ 5.0 mm2 led
to TLR rate of 9.6% in the ‘stentless’ PCI would have some value.
Clinical  implications/conclusionsFormerly in the era of balloon angioplasty alone, no bail out
tools were available when acute vessel closure resulting from elas-
tic recoil or dissection occurred. Furthermore, essential imaging
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atients undergoing PCI, given the selection of suitable patients
nd lesion types, if IVUS is aggressively used to assess the vessel
all and luminal gain, combined with optimal medical treatments.
hus, we believe a ‘stentless’ approach is applicable even in the DES
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